Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tongqiao Jingxuan Granules is a Traditional Chinese Medicine (TCM) developed by Jiuhua Huayuan Pharmaceutical for the treatment of benign paroxysmal positional vertigo (BPPV). Formulated as an innovative TCM (Class 1.1), it is designed to address the TCM syndrome of liver yang transforming into wind (肝阳化风), which is clinically associated with symptoms such as dizziness, vertigo, and nausea. The drug is intended to alleviate vertigo symptoms and reduce residual dizziness following canalith repositioning maneuvers. It received marketing approval from China's National Medical Products Administration (NMPA) in late 2023 based on clinical trials demonstrating its efficacy in improving recovery rates and symptom scores in BPPV patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tongqiao Jingxuan Granules.